Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.
Back to dashboard
Company Information
About this company
Key people
Charles W. Newhall
Independent Chairman of the Board
Frederick M. Hudson
Independent Director
Bethany L. Sensenig
Independent Director
Jack A. Khattar
President, Chief Executive Officer, Secretary, Director
Timothy C. Dec
Chief Financial Officer, Senior Vice President
Frank Mottola
Senior Vice President, Chief Technical Operations Officer
Padmanabh P. Bhatt
Senior Vice President - Intellectual Property, Chief Scientific Officer
William Todd Horich
Senior Vice President, Commercial Operations, Marketing, and Market Access
Jonathan Rubin
Senior Vice President, Chief Medical Officer - Research and Development
Carrolee Barlow
Independent Director
Georges Gemayel
Independent Director
Click to see more
Key facts
- Shares in issue58.22m
- EPICSUPN
- ISINUS8684591089
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$2.21bn
- Employees778
- ExchangeNASDAQ
- IndexS&P 600 Small Cap, TR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.